APEX MOLECULAR - Key Persons
Formerly Vice President of Avecia's Pharmaceutical Products business and CEO of Reaxa Ltd which was sold to Johnson Matthey. Peter is also co-founder and Non-Executive Director of Redx Pharma and founder of ADC Biotechnology and has over twenty five years' experience in the sector including the commercialisation of innovative technologies and forming, funding, development and exiting of technology start-ups. Peter provides Apex Molecular with valuable strategic guidance and commercial support.
Stuart joined Apex Molecular in 2014 and has jointly developed the company's business strategy and grown the customer portfolio. Previously he worked as an R&D Project Leader with Avecia, and prior to that worked as a Chemistry Team Leader at SAFC Pharma (formerly Ultrafine Chemicals Ltd). In both roles he was responsible for the technical management and delivery of customer projects. With 20 years' experience in the Chemical Industry Stuart brings a wealth of both technical and commercial experience to the company.
Thomas worked for six years at catalyst technology company Reaxa as R&D manager developing applications and variants of the company's encapsulated EnCatTM metal catalysts and new immobilisation technologies. He previously worked on FTE and custom synthesis projects at Peakdale Molecular and has a PhD and post-doctoral background in organic synthesis and catalytic reactions. An experienced project manager, including two RDA funded research projects and leading a current £1.4M multi-partner TSB supported project, and with nine years of technology and chemistry process development, Thomas will provide project management and line management for the company's operations.
Job Titles:
- Non - Executive Chairman
- Non - Executive Chairman Dr Stuart Brown - Chief Executive Officer Dr Tom Screen - Chief Operating Officer
- Venture Partner With Catapult 's GM & C Life Sciences Fund
We also have specific expertise in use of precious metal catalysis and catalytic coupling chemistry using generic or proprietary homogeneous and supported catalysts. With a background of working with the pharmaceutical industry we are very aware of the need to supply high purity and high-quality products.
Tony is a Venture Partner with Catapult's GM&C Life Sciences Fund, where he helps assess service company (CRO) investment opportunities and works with the Fund's smaller investments to enable companies to successfully grow. Tony is a well-known non-executive director and motivational speaker who co-founded Onyx Scientific in 2000 to offer contract chemistry services to many of the world's leading drug developers. He grew the business to become one the fastest growing technology companies in the UK, employing more than 60 staff at its peak, managed an MBO in 2007, and ultimately sold the business in 2011. Tony began his career as a Post-Doctoral Research Fellow, first with the Cancer Research Institute, and then with Oxford University. After a period as a Research Chemist with Dow Chemical he began the first of several business development roles.
Job Titles:
- Non - Executive Director
- Business Leader and Former COO of Cyprotex Prior to Its Sale to Evotec AG
Mark is an experienced business leader and former COO of Cyprotex prior to its sale to Evotec AG in 2014. He also has expertise in law previously specialising in corporate finance, venture capital and banking.